Turn this role into an interview — a resume and cover letter built around what this employer wants.
ScionxBio is seeking a visionary Vice President of Platform to lead its upstream RNA platform, reporting to the CEO and guiding AI-driven sequence design, formulation, and scalable delivery systems. You will steer long-range scientific strategy, build a multidisciplinary team, and translate validated modalities into durable medicines.
You will shape the platform direction, protect intellectual property, and partner with Discovery to transition optimized candidates into clinical development,
ScionxBio is engineering the next generation of RNA medicines, combining synthetic chemistry and artificial intelligence to create xRNA — a platform for long‑acting therapeutics. By expanding RNA beyond nature's four‑letter alphabet, we engineer molecules that sustain protein expression for weeks to months rather than days, with a lower immunogenic burden and the durability that chronic disease demands. At the heart of the platform is our TERA® engine, a closed‑loop system in which deep‑learning design, proprietary combinatorial assembly, high‑throughput screening, and continuous model retraining work together to optimise each molecule for its payload. With an initial focus on cardiometabolic disease, we are working to turn transient treatments into durable therapies. A spin‑out from Eleven Therapeutics, we are an international team operating across Cambridge (UK), Tel Aviv, and Cambridge (MA), with our Cambridge (UK) site serving as our largest research and development hub.
The Vice President of Platform is the architect of ScionxBio's core technology engine. Reporting to the CEO and sitting within the company's senior leadership, this individual owns the entire upstream pipeline — from computational design and AI‑driven sequence optimisation through to the formulation and delivery systems that carry our molecules into the body, and onward into the evolution of our next‑generation xRNA modalities. This is a rare opportunity to lead, and continue to build, the platform that defines the company: to set its scientific direction, to shape a multidisciplinary team of exceptional scientists and engineers, and to translate a validated modality into a durable, defensible, and endlessly generative source of medicines. We are looking for a scientific leader who is equally comfortable setting long‑range strategy and engaging deeply with the technical substance of the work.
Lead the development of our proprietary AI/ML models and computational biology pipelines for sequence design, structural prediction, and codon optimisation, with the goal of maximising translation, stability, and tissue specificity. This work is conducted in close collaboration with our strategic advisor.
Spearhead the continued strategic evolution of our modality, guiding the platform's advance into ever more sophisticated xRNA chemistries and ensuring that it remains firmly at the state of the art.
Oversee the formulation engineering team in optimising lipid nanoparticles (LNPs) for targeted, safe, and efficient in vivo delivery, again working in collaboration with our strategic advisor.
Ensure that platform discoveries are robust, reproducible, and engineered from the outset with manufacturing scalability in mind, so that what works at the bench translates reliably towards the clinic.
Own the resourcing, planning, and timelines for the platform team, and mentor and grow a multidisciplinary group of data scientists, biologists, and engineers into a high‑performing, collaborative whole.
Actively identify and protect novel sequence motifs, AI design algorithms, and proprietary LNP formulations, building and defending the intellectual property moat that underpins the company's long‑term value.
Serve as the pivotal bridge between Platform and Discovery, working closely with our chemistry and biology colleagues to transition optimised candidates smoothly from the Platform team into the Discovery team.
The opportunity to own and shape the defining technology platform of an ambitious, well‑founded biotech at a pivotal moment in its story; a seat within the senior leadership team, with real influence over the company's scientific direction; and the chance to build something durable alongside a talented, international community at the heart of the Cambridge life sciences ecosystem.